Literature DB >> 3190332

Pericardial substitutes: a survey.

W H Heydorn1, V A Ferraris, W R Berry.   

Abstract

Many thoracic surgeons have used pericardial substitutes to reduce the risk of reoperation, but there have been few reports of these procedures. Therefore, we used a questionnaire to gather information on experience with use of pericardial substitutes and to document the findings at reoperation. A six-question survey was sent to 2,344 members of The Society of Thoracic Surgeons, requesting surgeons to list their experience with pericardial substitutes and at reoperation in patients with these substitutes in place. Of the 634 surgeons who responded to the survey, 120 reported the insertion of 3,828 pericardial substitutes. Two hundred thirty-six reoperations were reported by 89 surgeons. None of the pericardial substitutes was reported to be completely successful in facilitating reoperation. The experience with polytetrafluoroethylene (PTFE) pericardial substitutes was reported to be significantly more satisfactory than that with all other substitutes (p = 0.0004 by chi-square analysis), but 14% of surgeons who used PTFE said they were dissatisfied at reoperation. Based on the results of this survey, we suggest caution, careful documentation, and long-term follow-up studies before widespread use of pericardial substitutes can be recommended.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3190332     DOI: 10.1016/s0003-4975(10)64699-1

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  2 in total

1.  Use of polytetrafluoroethylene surgical membrane as a pericardial substitute in the correction of congenital heart defects.

Authors:  M Loebe; V Alexi-Meskhishvili; Y Weng; G Hausdorf; R Hetzer
Journal:  Tex Heart Inst J       Date:  1993

2.  Suspected involvement of EPTFE membrane in sterile intrathoracic abscess and pericardial empyema in a multi-allergic LVAD recipient: a case report.

Authors:  A Kornberger; V Walter; M Khalil; P Therapidis; B Assmus; A Moritz; A Beiras-Fernandez; U A Stock
Journal:  J Cardiothorac Surg       Date:  2015-07-17       Impact factor: 1.637

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.